11.59
전일 마감가:
$11.79
열려 있는:
$11.76
하루 거래량:
1.98M
Relative Volume:
1.01
시가총액:
$989.56M
수익:
$65,400
순이익/손실:
$-46.34M
주가수익비율:
-12.60
EPS:
-0.92
순현금흐름:
$-38.74M
1주 성능:
-22.58%
1개월 성능:
-8.74%
6개월 성능:
+41.00%
1년 성능:
+181.31%
CorMedix Inc Stock (CRMD) Company Profile
명칭
CorMedix Inc
전화
908-517-9500
주소
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
CRMD을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CRMD
CorMedix Inc
|
11.59 | 989.56M | 65,400 | -46.34M | -38.74M | -0.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-07 | 개시 | Leerink Partners | Outperform |
2025-01-13 | 개시 | D. Boral Capital | Buy |
2024-08-26 | 개시 | Rodman & Renshaw | Buy |
2023-08-10 | 개시 | RBC Capital Mkts | Outperform |
2021-02-17 | 개시 | Needham | Buy |
2020-09-29 | 개시 | JMP Securities | Mkt Outperform |
2020-09-21 | 개시 | Truist | Buy |
2019-12-18 | 개시 | B. Riley FBR | Buy |
2019-03-26 | 재확인 | H.C. Wainwright | Buy |
2018-12-06 | 개시 | ROTH Capital | Buy |
2017-09-25 | 재확인 | H.C. Wainwright | Buy |
2017-08-10 | 재확인 | Rodman & Renshaw | Buy |
2017-05-05 | 재확인 | Rodman & Renshaw | Buy |
2016-11-11 | 재확인 | FBR & Co. | Outperform |
2016-03-17 | 재확인 | FBR Capital | Outperform |
2016-03-03 | 개시 | FBR Capital | Outperform |
2015-11-16 | 재확인 | ROTH Capital | Neutral |
2015-10-29 | 재확인 | ROTH Capital | Neutral |
2015-05-06 | 다운그레이드 | ROTH Capital | Buy → Neutral |
2014-12-08 | 재확인 | ROTH Capital | Buy |
2011-10-03 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
CorMedix Inc 주식(CRMD)의 최신 뉴스
Despite shrinking by US$64m in the past week, CorMedix (NASDAQ:CRMD) shareholders are still up 366% over 3 years - simplywall.st
CorMedix stock rises after earnings, revenue beat - MSN
CorMedix stock soars to 52-week high, hits $15.33 By Investing.com - Investing.com South Africa
CorMedix stock soars to 52-week high, hits $15.33 - Investing.com Australia
Long Term Trading Analysis for (CRMD) - news.stocktradersdaily.com
Cormedix anticipates Q2 revenue at high end of $23M-$31M range with inpatient growth accelerating - MSN
CorMedix at Jefferies Healthcare: Strategic Expansion and Financial Growth By Investing.com - Investing.com Canada
CorMedix at Jefferies Healthcare: Strategic Expansion and Financial Growth - Investing.com Australia
CorMedix stock rises as Q1 earnings and revenue surpass estimates By Investing.com - Investing.com Nigeria
CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position - Seeking Alpha
CorMedix:Exceeding Expectations (NASDAQ:CRMD) - Seeking Alpha
CorMedix Inc. to Present at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq
CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference - The Manila Times
CorMedix Brings Latest Therapeutic Developments to Jefferies Healthcare Conference 2025 - Stock Titan
(CRMD) Trading Advice - news.stocktradersdaily.com
CorMedix Inc. (CRMD) Stock Analysis: Unveiling a 37.30% Potential Upside in Healthcare Biotechnology - DirectorsTalk Interviews
CorMedix at RBC Capital Markets: Strategic Expansion and Growth - Investing.com Australia
CorMedix at RBC Capital Markets: Strategic Expansion and Growth By Investing.com - Investing.com India
CorMedix Inc. to Participate in the RBC Global Healthcare Conference - The Manila Times
CorMedix Inc. to Participate in RBC Capital Markets Global Healthcare Conference on May 21, 2025 - Nasdaq
Leading Biopharma CorMedix Set for Key Presentation at RBC Healthcare Conference Next Week - Stock Titan
CorMedix Inc. Makes NYSE MKT Section 610(b) Public Announcement - ACCESS Newswire
Surging Earnings Estimates Signal Upside for CorMedix (CRMD) Stock - Yahoo Finance
Market Highlights: CorMedix Inc (CRMD) Ends on a High Note at 12.03 - DWinneX
CorMedix Inc. Just Recorded A 22% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
CorMedix Inc. (CRMD): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential - Insider Monkey
Cormedix (CRMD) Receives a Buy from RBC Capital - The Globe and Mail
CorMedix at Citizens JMP: Strategic Growth and Market Expansion By Investing.com - Investing.com Nigeria
CorMedix at Citizens JMP: Strategic Growth and Market Expansion - Investing.com
CorMedix Inc. (NASDAQ:CRMD) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Just Shipped A Substantial Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Estimates - Yahoo Finance
CorMedix Inc. Reports Strong Q1 Earnings and Positive Outlook - MSN
CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates - MSN
(CRMD) Investment Analysis - news.stocktradersdaily.com
Earnings call transcript: CorMedix Q1 2025 results beat expectations, stock rises - Investing.com Nigeria
Cormedix Inc (CRMD) Q1 2025 Earnings Call Highlights: Record Profitability and Strategic Growth ... By GuruFocus - Investing.com Canada
CorMedix Inc. Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: CorMedix Q1 2025 results beat expectations, stock rises By Investing.com - Investing.com South Africa
CorMedix: Q1 Earnings Snapshot - Norwalk Hour
CorMedix Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CRMD Price Target Increased as Positive Momentum Builds | CRMD S - GuruFocus
CorMedix Shares Soar After Q1 Earnings, Revenue Beat Consensus - MarketScreener
CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025 - The Globe and Mail
Cormedix Inc (CRMD) Q1 2025 Earnings: EPS of $0.32 Beats Estimat - GuruFocus
CorMedix (CRMD) Surpasses Revenue and EPS Expectations in Q1 - GuruFocus
CRMD Price Target Increased as Positive Momentum Builds | CRMD Stock News - GuruFocus
CorMedix Inc. Revises Sales Guidance for the First Half of 2025 - marketscreener.com
CorMedix (CRMD) Surges on Strong Q1 Earnings - GuruFocus
CorMedix Inc (NASDAQ: CRMD): Hidden Gems In A Time Of Volatility - Stocksregister
CRMD Stock Rating and Price Target Maintained by Analyst | CRMD - GuruFocus
CorMedix Inc (CRMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
CorMedix Inc 주식 (CRMD) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Todisco Joseph | Chief Executive Officer |
Apr 01 '25 |
Option Exercise |
3.38 |
59,170 |
199,995 |
530,721 |
Mistry Erin | EVP, Chief Commercial Officer |
Oct 31 '24 |
Buy |
9.99 |
1,500 |
14,985 |
52,011 |
Hurlburt Elizabeth | EVP |
Nov 14 '24 |
Option Exercise |
4.48 |
140,027 |
627,727 |
185,424 |
Hurlburt Elizabeth | EVP |
Nov 14 '24 |
Sale |
11.18 |
140,027 |
1,565,670 |
45,397 |
자본화:
|
볼륨(24시간):